Literature DB >> 27867977

Immune checkpoint inhibition in patients with brain metastases.

Tanner Johanns1, Saiama N Waqar1, Daniel Morgensztern1.   

Abstract

Entities:  

Year:  2016        PMID： 27867977      PMCID： PMC5104596          DOI： 10.21037/atm.2016.09.40

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  21 in total

1.  Epidemiology of brain metastases.

Authors:  Lakshmi Nayak; Eudocia Quant Lee; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.

Authors:  Noël E C Schartz; Cécile Farges; Isabelle Madelaine; Heriberto Bruzzoni; Fabien Calvo; Axel Hoos; Céleste Lebbé
Journal:  Melanoma Res       Date:  2010-06       Impact factor: 3.599

3.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

Authors:  Kim Margolin; Marc S Ernstoff; Omid Hamid; Donald Lawrence; David McDermott; Igor Puzanov; Jedd D Wolchok; Joseph I Clark; Mario Sznol; Theodore F Logan; Jon Richards; Tracy Michener; Agnes Balogh; Kevin N Heller; F Stephen Hodi
Journal:  Lancet Oncol       Date:  2012-03-27       Impact factor: 41.316

4.  Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.

Authors:  Maria-Polina Konstantinou; Caroline Dutriaux; Caroline Gaudy-Marqueste; Laurent Mortier; Christophe Bedane; Céline Girard; Sophie Thellier; Thomas Jouary; Jean-Jacques Grob; Marie-Aleth Richard; Caroline Templier; Lilia Sakji; Bernard Guillot; Carle Paul; Nicolas Meyer
Journal:  Acta Derm Venereol       Date:  2014-01       Impact factor: 4.437

5.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

Review 7.  Targeting T Cell Co-receptors for Cancer Therapy.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

Review 10.  Updates in the management of brain metastases.

Authors:  Nils D Arvold; Eudocia Q Lee; Minesh P Mehta; Kim Margolin; Brian M Alexander; Nancy U Lin; Carey K Anders; Riccardo Soffietti; D Ross Camidge; Michael A Vogelbaum; Ian F Dunn; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2016-08       Impact factor: 12.300
View more
  5 in total

Review 1.  Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.

Authors:  Mark Owyong; Niloufar Hosseini-Nassab; Gizem Efe; Alexander Honkala; Renske J E van den Bijgaart; Vicki Plaks; Bryan Ronain Smith
Journal:  Drug Resist Updat       Date:  2017-10-14       Impact factor: 18.500

2.  Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.

Authors:  Qingyuan Huang; Hua Zhang; Josephine Hai; Mark A Socinski; Eric Lim; Haiquan Chen; Justin Stebbing
Journal:  Oncoimmunology       Date:  2018-06-20       Impact factor: 8.110

Review 3.  Emerging Role of PD-1 in the Central Nervous System and Brain Diseases.

Authors:  Junli Zhao; Alexus Roberts; Zilong Wang; Justin Savage; Ru-Rong Ji
Journal:  Neurosci Bull       Date:  2021-04-20       Impact factor: 5.271

Review 4.  Mechanisms and Therapy for Cancer Metastasis to the Brain.

Authors:  Federica Franchino; Roberta Rudà; Riccardo Soffietti
Journal:  Front Oncol       Date:  2018-05-24       Impact factor: 6.244

Review 5.  Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System.

Authors:  Mohini Singh; David Bakhshinyan; Chitra Venugopal; Sheila K Singh
Journal:  Front Oncol       Date:  2017-09-19       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.